Effect of L-dopa with and without inhibition of extra cerebral dopa decarboxylase on gastric acid secretion and gastrin release in man
- PMID: 4054700
- PMCID: PMC1432960
- DOI: 10.1136/gut.26.10.1014
Effect of L-dopa with and without inhibition of extra cerebral dopa decarboxylase on gastric acid secretion and gastrin release in man
Abstract
The present study was undertaken to investigate the possibility that central nervous system monoaminergic pathways may play a role in the control of gastric acid and gastrin secretion in man. Submaximal pentagastrin stimulated (0.25 micrograms/kg/h) gastric acid secretion, as well as basal gastrin concentrations were studied in two groups of subjects. The first group received oral administration of placebo and the catecholamine precursor L-dopa (500 mg); the second group was treated with placebo and the association of L-dopa (100 mg) plus carbidopa (35 mg) after pretreatment with carbidopa (50 mg every six hours for four doses), a schedule which is known to increase brain catecholamine concentrations. In comparison with placebo, stimulated gastric acid secretion was reduced by L-dopa alone, whereas was not modified by L-dopa plus carbidopa. Basal gastrin concentrations were increased after L-dopa and after L-dopa plus carbidopa. These data show that basal gastrin concentration is raised by central catecholamine augmentation; but gastric acid secretion seems to be influenced by changes of peripheral catecholamine concentrations. It is suggested that dopamine and perhaps noradrenaline, but not adrenaline, are important in these effects.
Similar articles
-
Inhibition of the renin-angiotensin-aldosterone system by L-dopa with and without inhibition of extracerebral dopa decarboxylase in man.Clin Sci (Lond). 1981 Aug;61(2):187-90. doi: 10.1042/cs0610187. Clin Sci (Lond). 1981. PMID: 7021041 Clinical Trial.
-
Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.J Clin Invest. 1978 Apr;61(4):973-80. doi: 10.1172/JCI109022. J Clin Invest. 1978. PMID: 659585 Free PMC article.
-
Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.DNA Cell Biol. 2012 Nov;31(11):1572-9. doi: 10.1089/dna.2011.1546. Epub 2012 Sep 28. DNA Cell Biol. 2012. PMID: 23020119
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
-
Levodopa.2021 Oct 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Oct 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644043 Free Books & Documents. Review.
Cited by
-
Soporific Effect of Modified Suanzaoren Decoction and Its Effects on the Expression of CCK-8 and Orexin-A.Evid Based Complement Alternat Med. 2020 Jun 16;2020:6984087. doi: 10.1155/2020/6984087. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32617111 Free PMC article.
-
Effects of FCE20700, a new PGE2 derivative, on gastric acid secretion and cytoprotective processes in man.Eur J Clin Pharmacol. 1987;31(5):535-9. doi: 10.1007/BF00606626. Eur J Clin Pharmacol. 1987. PMID: 3830240 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources